J Korean Med Assoc.  2016 Jan;59(1):24-30. 10.5124/jkma.2016.59.1.24.

Hypertension in pregnancy

• Koo YJ
• Lee DH

• KMID: 2195164
• DOI: http://doi.org/10.5124/jkma.2016.59.1.24

Abstract

Hypertension is the most common medical disorder encountered in pregnancy, complicating 5% to 10% of all pregnancies. It is a major cause of maternal, fetal and newborn morbidity and mortality, increasing the risk of cerebrovascular events, organ failure and placenta abruptio in mothers and the risk of intrauterine growth restriction, prematurity and intrauterine death in fetuses. There are four types of hypertensive disorders in pregnancy: gestational hypertension, preeclampsia and eclampsia syndrome, chronic hypertension of any etiology, and Preeclampsia superimposed on chronic hypertension. The decision to treat hypertension in pregnancy should consider the benefit-harm balance for both mother and fetus, and depends on gestational age, blood pressure levels, and presence of preeclampsia. As termination of pregnancy is the only cure for preeclampsia, there is general agreement that delivery rather than observation is suggested in women with severe preeclampsia, eclampsia, or mild hypertension at term. However, it is not clear whether women with mild hypertension at near term can be managed expectantly as well as whether antihypertensive therapy for mild to moderate hypertension should be initiated. In 2013, the American College of Obstetricians and Gynecologists provided evidence-based recommendations for the management of patients with hypertension during and after pregnancy, but it concluded that the final decision should be individualized and made by the health care provider and patient in all instances. Therefore, well-designed large trials are needed to clarify the indication for antihypertensive use and the selected population who would benefit from expectant management for mild to moderate hypertension at preterm.

Keyword

Hypertension; Pregnancy; Pre-eclampsia; Disease management

MeSH Terms

Blood Pressure
Disease Management
Eclampsia
Female
Fetus
Gestational Age
Health Personnel
Humans
Hypertension*
Hypertension, Pregnancy-Induced
Infant, Newborn
Mortality
Mothers
Placenta
Pre-Eclampsia
Pregnancy*

Reference

1. Statistics Korea. Mortality statistics 2013 [Internet]. Daejeon: Statistics Korea;2014. cited 2015 Nov 4. Available from: http://www.index.go.kr/potal/main/EachDtlPageDetail.do?idx_cd=2769.

2. Berg CJ, Harper MA, Atkinson SM, Bell EA, Brown HL, Hage ML, Mitra AG, Moise KJ Jr, Callaghan WM. Preventability of pregnancy-related deaths: results of a state-wide review. Obstet Gynecol. 2005; 106:1228–1234.

3. Say L, Chou D, Gemmill A, Tuncalp O, Moller AB, Daniels J, Gulmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014; 2:e323–e333.

4. Meher S, Abalos E, Carroli G. Bed rest with or without hospi-talisation for hypertension during pregnancy. Cochrane Database Syst Rev. 2005; (4):CD003514.

5. American College of Obstetricians and Gynecologists. Task Force on Hypertension in Pregnancy. Hypertension in preg-nancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. Obstet Gynecol. 2013; 122:1122–1131.

6. Langenveld J, Ravelli AC, van Kaam AH, van der Ham DP, van Pampus MG, Porath M, Mol BW, Ganzevoort W. Neonatal outcome of pregnancies complicated by hypertensive disorders between 34 and 37 weeks of gestation: a 7 year retrospective analysis of a national registry. Am J Obstet Gynecol. 2011; 205:540.

7. Koopmans CM, Bijlenga D, Groen H, Vijgen SM, Aarnoudse JG, Bekedam DJ, van den Berg PP, de Boer K, Burggraaff JM, Bloemenkamp KW, Drogtrop AP, Franx A, de Groot CJ, Huisjes AJ, Kwee A, van Loon AJ, Lub A, Papatsonis DN, van der Post JA, Roumen FJ, Scheepers HC, Willekes C, Mol BW, van Pampus MG. HYPITAT study group. Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial. Lancet. 2009; 374:979–988.

8. Practice Bulletin no. 145: antepartum fetal surveillance. Obstet Gynecol. 2014; 124:182–192.

9. Bombrys AE, Barton JR, Nowacki EA, Habli M, Pinder L, How H, Sibai BM. Expectant management of severe preeclampsia at less than 27 weeks' gestation: maternal and perinatal outcomes according to gestational age by weeks at onset of expectant management. Am J Obstet Gynecol. 2008; 199:247.e1–247.e6.

10. Sibai BM, Mercer BM, Schiff E, Friedman SA. Aggressive ver-sus expectant management of severe preeclampsia at 28 to 32 weeks' gestation: a randomized controlled trial. Am J Obstet Gynecol. 1994; 171:818–822.

11. Publications Committee, Society for Maternal-Fetal Medicine. Sibai BM. Evaluation and management of severe preeclampsia before 34 weeks' gestation. Am J Obstet Gynecol. 2011. 205:p. 191–198.

12. Lucas MJ, Leveno KJ, Cunningham FG. A comparison of mag-nesium sulfate with phenytoin for the prevention of eclampsia. N Engl J Med. 1995; 333:201–205.

13. Nguyen TM, Crowther CA, Wilkinson D, Bain E. Magnesium sulphate for women at term for neuroprotection of the fetus. Cochrane Database Syst Rev. 2013; 2:CD009395.

14. Sibai BM, Gonzalez AR, Mabie WC, Moretti M. A comparison of labetalol plus hospitalization versus hospitalization alone in the management of preeclampsia remote from term. Obstet Gynecol. 1987; 70:323–327.

15. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2014; 2:CD002252.

16. Sibai BM. Chronic hypertension in pregnancy. Obstet Gynecol. 2002; 100:369–377.

17. Nakhai-Pour HR, Rey E, Berard A. Discontinuation of antihy-pertensive drug use during the first trimester of pregnancy and the risk of preeclampsia and eclampsia among women with chronic hypertension. Am J Obstet Gynecol. 2009; 201:180.e1–180.e8.

18. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S. Guideline Development Group. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ. 2010; 341:c2207.

19. European Society of Gynecology (ESG). Association for Euro-pean Paediatric Cardiology (AEPC). German Society for Gen-der Medicine (DGesGM). Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, Gibbs JS, Gohlke-Baerwolf C, Gorenek B, Iung B, Kirby M, Maas AH, Morais J, Nihoyannopoulos P, Pieper PG, Presbitero P, Roos-Hesselink JW, Schaufelberger M, Seeland U, Torracca L. ESC Committee for Practice Guidelines. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32:3147–3197.

20. Kintiraki E, Papakatsika S, Kotronis G, Goulis DG, Kotsis V. Pregnancy-induced hypertension. Hormones (Athens). 2015; 14:211–223.